As previously reported, BofA analyst Alec Stranahan downgraded Y-mAbs Therapeutics (YMAB) to Underperform from Neutral with a price target of $3, down from $12. The firm sees continued headwinds for the already slowing launch of Danyelza for high-risk neuroblastoma, sees more work to be done on dose optimization for GD2-SADA for solid tumors and thinks Y-mAbs’ cash position could create a funding gap, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
- Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
- Positive Outlook on Y-Mabs Therapeutics Despite Adjusted Price Target, Driven by Promising Radiopharmaceutical Platform
- Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA
- Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist